


**Financial Statements 2024-2025**  
**Second Quarter**  
**(Unaudited)**



**SQUARE PHARMACEUTICALS PLC.**  
**(Consolidated and Separate)**



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Financial Position

As at 31 December 2024

Particulars	Notes	31 Dec 2024 Taka	30 Jun 2024 Taka
<b>ASSETS</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	02	30,161,061,265	27,750,005,864
Investment in Associates	03	19,063,882,673	17,397,060,559
Investment in Marketable Securities	04	9,830,546,374	9,292,402,647
Long Term Investment - Others	05	7,532,309,610	6,992,206,904
		<b>66,587,799,922</b>	<b>61,431,675,974</b>
<b>Current Assets:</b>			
Inventories	06	14,592,316,388	12,582,152,295
Trade and Other Receivables	07	4,647,246,897	4,503,386,212
Advances, Deposits and Prepayments	08	1,991,084,233	2,106,522,837
Cash and Cash Equivalents	09	57,752,836,503	52,013,459,742
		<b>78,983,484,021</b>	<b>71,205,521,086</b>
<b>TOTAL ASSETS</b>		<b>145,571,283,943</b>	<b>132,637,197,060</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY:</b>			
Share Capital		8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
General Reserve		105,878,200	105,878,200
Fair Value Reserve	10	(167,909,431)	(275,040,481)
Tax Holiday Reserve	11	1,674,592,803	951,511,612
Translation Reserve	12	124,606,724	97,906,017
Retained Earnings	13	116,359,875,096	114,139,071,906
<b>Attributable to Equity Holders</b>		<b>128,997,018,492</b>	<b>125,919,302,354</b>
Non-Controlling Interests	14	3,870,404	2,318,478
<b>TOTAL EQUITY</b>		<b>129,000,888,896</b>	<b>125,921,620,832</b>
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities</b>			
Long Term Loan	15.1	510,219,792	814,539,826
Deferred Tax Liabilities	16	569,086,141	619,081,523
		<b>1,079,305,933</b>	<b>1,433,621,349</b>
<b>Current Liabilities</b>			
Long Term Loan - Current Portion	15.2	620,439,578	614,539,826
Trade Payables		1,325,420,965	1,455,428,272
Other Payables	17	11,822,935,739	1,820,943,973
Current Tax Liabilities	18	1,274,954,392	912,265,905
Accrued Expenses	19	261,226,667	286,793,273
Unclaimed Dividend		186,111,773	191,983,630
		<b>15,491,089,114</b>	<b>5,281,954,879</b>
<b>TOTAL LIABILITIES</b>		<b>16,570,395,047</b>	<b>6,715,576,228</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>145,571,283,943</b>	<b>132,637,197,060</b>
<b>Net Assets Value (NAV) per Share</b>	30	<b>145.52</b>	<b>142.05</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Quarter Ended 31 December 2024

Particulars	Notes	Six-Month Result		2nd Quarter Result	
		July'24 - Dec'24	July'23 - Dec'23	Oct'24 - Dec'24	Oct'23 - Dec'23
		Taka	Taka	Taka	Taka
<b>Net Revenue</b>	20	<b>37,717,778,672</b>	<b>35,552,503,593</b>	<b>19,970,891,107</b>	<b>17,741,265,448</b>
Cost of Goods Sold	21	(19,893,431,304)	(18,084,962,081)	(11,064,971,566)	(9,429,269,449)
<b>Gross Profit</b>		<b>17,824,347,368</b>	<b>17,467,541,512</b>	<b>8,905,919,541</b>	<b>8,311,995,999</b>
Selling and Distribution Expenses	22	(6,045,429,884)	(5,270,833,021)	(2,987,891,424)	(2,788,716,297)
Administrative Expenses	23	(884,315,155)	(829,829,307)	(444,968,847)	(456,234,011)
Finance Cost	24	(127,200,832)	(99,669,079)	(58,405,306)	(58,267,267)
<b>Operating Expenses</b>		<b>(7,056,945,871)</b>	<b>(6,200,331,407)</b>	<b>(3,491,265,577)</b>	<b>(3,303,217,575)</b>
<b>Profit before Other Operating Income</b>		<b>10,767,401,497</b>	<b>11,267,210,105</b>	<b>5,414,653,964</b>	<b>5,008,778,424</b>
Other Operating Income	25	227,776,534	128,427,559	16,521,154	12,880,353
<b>Profit from Operations</b>		<b>10,995,178,031</b>	<b>11,395,637,664</b>	<b>5,431,175,118</b>	<b>5,021,658,777</b>
Income from Investments	26	3,056,110,856	2,137,688,825	1,591,890,211	1,050,282,114
<b>Profit before contribution to WPPF &amp; WWF</b>		<b>14,051,288,887</b>	<b>13,533,326,489</b>	<b>7,023,065,329</b>	<b>6,071,940,891</b>
Contribution to WPPF & WWF	27	(665,805,097)	(652,184,353)	(332,994,252)	(292,113,630)
<b>Profit before Tax</b>		<b>13,385,483,790</b>	<b>12,881,142,136</b>	<b>6,690,071,077</b>	<b>5,779,827,261</b>
Current Tax (Expense)		(2,424,802,712)	(2,565,675,430)	(1,213,618,964)	(1,060,140,659)
Deferred Tax (Expense) / Income		68,899,866	(82,124,872)	29,440,774	(126,999,229)
<b>Income Tax Expense</b>	28	<b>(2,355,902,846)</b>	<b>(2,647,800,302)</b>	<b>(1,184,178,190)</b>	<b>(1,187,139,888)</b>
<b>Profit after Tax</b>		<b>11,029,580,944</b>	<b>10,233,341,834</b>	<b>5,505,892,887</b>	<b>4,592,687,373</b>
Profit from Associate Undertakings	03	1,666,822,114	1,012,618,795	1,097,859,900	652,559,010
<b>Profit for the Period</b>		<b>12,696,403,058</b>	<b>11,245,960,629</b>	<b>6,603,752,787</b>	<b>5,245,246,383</b>
Net Unrealised Gain/(Loss) on Marketable Securities	29	107,125,409	1,314,074	(612,157,967)	(86,329,886)
Translation Adjustment for the Period	12	26,700,706	(62,349,088)	(115,257)	(36,283,929)
<b>Other Comprehensive Income</b>		<b>133,826,115</b>	<b>(61,035,014)</b>	<b>(612,273,224)</b>	<b>(122,613,815)</b>
<b>Total Comprehensive Income</b>		<b>12,830,229,173</b>	<b>11,184,925,615</b>	<b>5,991,479,563</b>	<b>5,122,632,568</b>
<b>Profit for the Period Attributable to:</b>					
Equity Holders of the Company		12,694,845,491	11,245,360,669	6,602,927,921	5,244,982,421
Non-Controlling Interest		1,557,567	599,960	824,866	263,962
		<b>12,696,403,058</b>	<b>11,245,960,629</b>	<b>6,603,752,787</b>	<b>5,245,246,383</b>
<b>Total Comprehensive Income Attributable to:</b>					
Equity Holders of the Company		12,828,677,248	11,184,325,831	5,990,666,397	5,122,368,636
Non-Controlling Interest		1,551,925	599,784	813,166	263,932
		<b>12,830,229,173</b>	<b>11,184,925,615</b>	<b>5,991,479,563</b>	<b>5,122,632,568</b>
<b>Earnings Per Share (EPS)</b>	31	<b>14.32</b>	<b>12.69</b>	<b>7.45</b>	<b>5.92</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Changes in Equity

For the Quarter Ended 31 December 2024

Particulars	Attributable to Equity Holders								Non-Controlling Interests Taka	Total Equity Taka
	Share Capital Taka	Share Premium Taka	General Reserve Taka	Fair Value Reserve Taka	Tax Holiday Reserve Taka	Translation Reserve Taka	Retained Earnings Taka	Total Taka		
<b>As At 01 July 2023</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>734,507,296</b>	<b>133,398,880</b>	<b>(16,905,546)</b>	<b>103,339,085,459</b>	<b>115,195,939,389</b>	<b>709,376</b>	<b>115,196,648,765</b>
Profit for the Period	-	-	-	-	-	-	11,245,360,669	11,245,360,669	599,960	11,245,960,629
Other Comprehensive Income	-	-	-	1,314,249	-	(62,349,088)	-	(61,034,839)	(176)	(61,035,015)
Tax Holiday Reserve	-	-	-	-	333,831,164	-	(333,831,164)	-	-	-
Cash Dividend (2022-23)	-	-	-	-	-	-	(9,307,735,605)	(9,307,735,605)	-	(9,307,735,605)
<b>As At 31 December 2023</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>735,821,545</b>	<b>467,230,044</b>	<b>(79,254,634)</b>	<b>104,942,879,360</b>	<b>117,072,529,615</b>	<b>1,309,160</b>	<b>117,073,838,775</b>
<b>As At 01 July 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(275,040,481)</b>	<b>951,511,612</b>	<b>97,906,017</b>	<b>114,139,071,906</b>	<b>125,919,302,354</b>	<b>2,318,478</b>	<b>125,921,620,832</b>
Profit for the Period	-	-	-	-	-	-	12,694,845,491	12,694,845,491	1,557,567	12,696,403,058
Other Comprehensive Income	-	-	-	107,131,050	-	26,700,707	-	133,831,757	(5,641)	133,826,116
Tax Holiday Reserve	-	-	-	-	723,081,191	-	(723,081,191)	-	-	-
Cash Dividend (2023-24)	-	-	-	-	-	-	(9,750,961,110)	(9,750,961,110)	-	(9,750,961,110)
<b>As At 31 December 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(167,909,431)</b>	<b>1,674,592,803</b>	<b>124,606,724</b>	<b>116,359,875,096</b>	<b>128,997,018,492</b>	<b>3,870,404</b>	<b>129,000,888,896</b>

The annexed notes form an integral part of these financial statements

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Consolidated Statement of Cash Flows

For the Quarter Ended 31 December 2024

Particulars	Notes	July'24 - Dec'24 Taka	July'23 - Dec'23 Taka
<b>Cash Flows from Operating Activities:</b>			
Receipts from Customers		43,488,770,640	42,181,114,091
Receipts from Others		35,222,668	122,141,625
Payments to Suppliers		(16,232,342,292)	(11,043,718,090)
Payments for Manufacturing and Operating Expenses		(11,553,272,186)	(11,578,598,715)
Payment of Value Added Tax		(5,888,888,824)	(5,302,400,768)
<b>Cash Generated from Operations</b>		<b>9,849,490,006</b>	<b>14,378,538,143</b>
Interest Paid		(132,285,858)	(103,323,442)
Payment of Income Tax		(1,862,114,225)	(1,875,910,781)
Payment of WPPF & WF		(536,159,925)	(575,771,720)
Others		16,578,750	917,047,821
<b>Net Cash from Operating Activities</b>		<b>7,335,508,748</b>	<b>12,740,580,021</b>
<b>Cash Flows from Investing Activities:</b>			
Purchase of Property, Plant and Equipment		(3,467,778,772)	(854,972,553)
Proceeds from Sale of Property, Plant and Equipment		22,309,353	-
Long Term Investment - Others		(540,102,706)	(1,939,594,992)
Investment in Marketable Securities		(318,920,914)	(3,774,550,312)
Interest Received		2,708,416,424	1,762,743,936
Dividends Received		127,564,112	14,816,295
<b>Net Cash from/(Used in) Investing Activities</b>		<b>(1,468,512,503)</b>	<b>(4,791,557,626)</b>
<b>Cash Flows from Financing Activities:</b>			
Payment of Dividend		(5,871,856)	(8,508,143)
Proceeds from/Payment of Term Loan and Bank Overdraft		(298,420,282)	(371,406,157)
<b>Net Cash Used in Financing Activities</b>		<b>(304,292,138)</b>	<b>(379,914,300)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>		<b>5,562,704,107</b>	<b>7,569,108,095</b>
Cash and Cash Equivalents at 01 July	09	52,013,459,742	50,094,321,854
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents		176,672,654	(226,201)
<b>Cash and Cash Equivalents at 31 December</b>	09	<b>57,752,836,503</b>	<b>57,663,203,748</b>
<b>Net Operating Cash Flow (NOCF) per Share</b>	32	<b>8.28</b>	<b>14.37</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Notes to the Consolidated Financial Statements For the Quarter Ended 31 December 2024

### 01. Basis of Preparation of the Interim Financial Statements:

These Financial Statements are the unaudited consolidated interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913; Square Pharmaceuticals Kenya EPZ Ltd., incorporated in Kenya under Companies Act, 2015, Kenya; Square Lifesciences Ltd., incorporated in Bangladesh under Companies Act, 1994, and Samson Pharma Inc., incorporated under Revised Corporation Code of the Philippines, 2019 for the 2nd Quarter Ended on December 31, 2024. These are prepared in accordance with IAS 34 - 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2024, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below, Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understand that the business is growing every year that means the assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if disposed at reporting date. At present, there is no intention to dispose these assets. Therefore, it is not required to record the impairment gain.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

#### Foreign Currency Translation:

The Financials of Square Pharmaceuticals Kenya EPZ Ltd. have been drawn in KHS (Kenyan Shilling) as reporting currency in Kenya. These Financials are converted in BDT to consolidate with the Financials of Square Pharmaceuticals PLC. as the parent company. 1 KES = 0.928127 BDT as at 31 December 2024.

### 02. Consolidated Property, Plant and Equipment: Tk. 30,161,061,265

#### Cost:

	31 Dec 2024	30 Jun 2024
Opening Balance	50,654,228,044	47,837,735,674
Translation Adjustments to opening balance	42,228,621	221,339,254
Addition during the Period/Year	813,804,304	2,918,957,136
	51,510,260,969	50,978,032,064
Disposal/Transfer during the Period/Year	(45,031,480)	(323,804,020)
<b>Tk.</b>	<b>51,465,229,489</b>	<b>50,654,228,044</b>

#### Accumulated Depreciation:

Opening Balance	25,796,547,715	23,576,848,855
Translation Adjustments to opening balance	8,422,472	31,894,803
Charged for the Period/Year	1,069,944,207	2,318,653,384
	26,874,914,394	25,927,397,042
Disposal/Transfer during the Period/Year	(31,408,767)	(130,849,327)
<b>Tk.</b>	<b>26,843,505,627</b>	<b>25,796,547,715</b>

#### Net Book Value

Consolidated Property, Plant and Equipment in Transit (Note - 02.1)	24,621,723,862	24,857,680,329
Consolidated Building under Construction (Note - 02.2)	991,882,044	1,118,740,924
Consolidated Capital Work-in-Progress (Note - 02.3)	4,546,714,674	1,773,584,611
	740,685	-
<b>Tk.</b>	<b>30,161,061,265</b>	<b>27,750,005,864</b>

### 02.1 Consolidated Property, Plant and Equipment in Transit: Tk. 991,882,044

Opening Balance	1,118,740,924	715,369,536
Addition during the Period/Year	584,331,742	1,134,336,770
	1,703,072,666	1,849,706,306
Transfer during the Period/Year	(711,190,622)	(730,965,382)
<b>Tk.</b>	<b>991,882,044</b>	<b>1,118,740,924</b>

### 02.2 Consolidated Building under Construction: Tk. 4,546,714,674

Opening Balance	1,773,584,611	1,081,705,847
Addition during the Period/Year	2,773,130,063	1,063,055,568
	4,546,714,674	2,144,761,415
Transfer during the Period/Year	-	(371,176,804)
<b>Tk.</b>	<b>4,546,714,674</b>	<b>1,773,584,611</b>

### 02.3 Consolidated Capital Work-in-Progress: Tk. 740,685

Opening Balance	-	859,697
Addition during the Period/Year	740,685	-
	740,685	859,697
Transfer during the Period/Year	-	(859,697)
<b>Tk.</b>	<b>740,685</b>	<b>-</b>

### 03. Consolidated Investment in Associates: Tk. 19,063,882,673

Opening Balance		17,397,060,559.00	15,076,807,755
Add: Profit/(Loss) during the Period/Year:	<b>Proportion of Ownership</b>		
Square Textiles PLC.	46.36%	317,274,180.00	501,534,080
Square Fashions Ltd.	48.63%	1,210,993,332.00	1,858,942,218
Square Hospitals Ltd.	49.94%	138,554,602.00	234,086,537
		1,666,822,114.00	2,594,562,835
Less: Dividend received during the Period/Year		-	(274,310,031)
<b>Tk.</b>		<b>19,063,882,673.00</b>	<b>17,397,060,559</b>

### 04. Consolidated Investment in Marketable Securities: Tk. 9,830,546,374

#### 04.1 Cost: Tk. 10,028,095,911

Opening Balance	9,615,982,078	3,773,747,813
Addition during the Period/Year	529,119,524	5,944,648,543
Sold during the Period/Year	(117,005,691)	(102,414,278)
<b>Tk.</b>	<b>10,028,095,911</b>	<b>9,615,982,078</b>

#### 04.2 Market Value: Tk. 9,830,546,374

Opening Balance	9,292,402,647	4,589,867,031
Addition during the Period/Year	748,342,337	4,814,862,652
Sold during the Period/Year	(210,198,610)	(112,327,036)
<b>Tk.</b>	<b>9,830,546,374</b>	<b>9,292,402,647</b>

	31 Dec 2024	30 Jun 2024
<b>05. Consolidated Long Term Investment - Others: Tk. 7,532,309,610</b>		
<b>05.1 Ordinary Shares (Unquoted): Tk. 127,694,430</b>		
(i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)	12,000,000	12,000,000
(ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)	15,694,430	15,694,430
(iii) FAM - First Fixed Income Fund (1,000 Units of Tk. 100,000/- each)	100,000,000	100,000,000
<b>Tk.</b>	<b>127,694,430</b>	<b>127,694,430</b>
<b>05.2 Non-Convertible Zero Coupon Bonds: Tk. 304,615,180</b>		
(i) LankaBangla Finance Ltd.	-	67,033,336
(ii) Brac Bank Ltd. (200 Bonds)	187,659,050	238,677,650
(iii) IDLC Finance Ltd. (240 Bonds)	116,956,130	158,801,488
<b>Tk.</b>	<b>304,615,180</b>	<b>464,512,474</b>
<b>05.3 Non-Convertible Subordinated Bonds: Tk. 7,100,000,000</b>		
(i) Mutual Trust Bank Ltd. (220 Bonds)	2,200,000,000	2,200,000,000
(ii) Southeast Bank Ltd. (3,000 Bonds)	300,000,000	400,000,000
(iii) Islami Bank Bangladesh Ltd. (30 Bonds)	300,000,000	400,000,000
(iv) Trust Bank Ltd. (30 Bonds)	300,000,000	400,000,000
(v) Eastern Bank Ltd. (50 Bonds)	500,000,000	500,000,000
(vi) Prime Bank Ltd. (100 Bonds)	1,000,000,000	1,000,000,000
(vii) Dutch Bangla Bank Ltd. (150 Bonds)	1,500,000,000	1,500,000,000
(viii) Shahjalal Islami Bank PLC. (1000 Bonds)	1,000,000,000	-
<b>Tk.</b>	<b>7,100,000,000</b>	<b>6,400,000,000</b>
<b>Tk.</b>	<b>7,532,309,610</b>	<b>6,992,206,904</b>
<b>06. Consolidated Inventories: Tk. 14,592,316,388</b>		
Raw Materials	5,455,115,936	4,801,972,525
Packing Materials	1,693,669,381	1,272,032,952
Work-in-Process	940,413,948	784,057,550
Finished Goods	4,901,624,434	3,825,932,863
Spares & Accessories	1,310,145,769	1,044,608,061
Goods- in-Transit	291,346,920	853,548,344
<b>Tk.</b>	<b>14,592,316,388</b>	<b>12,582,152,295</b>
<b>07. Consolidated Trade and Other Receivables: Tk. 4,647,246,897</b>		
Trade Receivables	2,567,860,697	2,551,026,541
Other Receivables (Note - 7.1)	2,079,386,200	1,952,359,671
<b>Tk.</b>	<b>4,647,246,897</b>	<b>4,503,386,212</b>
<b>07.1 Consolidated Other Receivables: Tk. 2,079,386,200</b>		
Interest Receivable from Fixed Deposit Receipts	1,647,266,098	1,520,761,823
Interest Receivable from Short Notice Deposits	7,462,258	1,300
Gain against Zero Coupon Bonds (Receivable)	69,529,676	87,443,698
Interest Receivable from Subordinated Bonds	58,210,958	47,324,767
Accrued Income	66,917,210	66,828,083
Insurance Claim Receivable	230,000,000	230,000,000
<b>Tk.</b>	<b>2,079,386,200</b>	<b>1,952,359,671</b>
<b>08. Consolidated Advances, Deposits and Prepayments: Tk. 1,991,084,233</b>		
<b>08.1 Advances: Tk. 1,018,098,459</b>		
Employees	289,167,467	283,810,814
Advance Income Tax	14,738,457	214,738,457
Land Purchase	91,044,000	84,081,400
Suppliers	623,148,535	616,316,380
<b>Tk.</b>	<b>1,018,098,459</b>	<b>1,198,947,051</b>
<b>08.2 Deposits: Tk. 912,824,494</b>		
Value Added Tax	488,222,883	387,160,183
Earnest Money & Security Deposit	389,324,749	405,903,499
Others	35,276,862	13,001,014
<b>Tk.</b>	<b>912,824,494</b>	<b>806,064,696</b>
<b>08.3 Prepayments: Tk. 60,161,280</b>		
Office Rent	23,032,440	23,242,440
Insurance Premium	37,128,840	78,268,650
<b>Tk.</b>	<b>60,161,280</b>	<b>101,511,090</b>
<b>Tk.</b>	<b>1,991,084,233</b>	<b>2,106,522,837</b>
<b>09. Cash and Cash Equivalents: Tk. 57,752,836,503</b>		
<b>09.1 Cash in Hand</b>		
<b>09.2 Cash at Bank: Tk. 26,041,268,163</b>		
Current Accounts	313,107,981	112,392,110
STD & SND Accounts	15,009,772,474	14,182,411,481
Export Retention Quota Accounts (held in USD)	179,425,856	174,360,222
Margin Held Accounts (held in USD)	601,856,167	525,205,243
Dividend Accounts	9,937,105,686	191,983,630
<b>Tk.</b>	<b>26,041,268,163</b>	<b>15,186,352,686</b>
<b>09.3 Fixed Deposit Receipts (FDRs): Tk. 31,559,989,167</b>		
FDRs held in BDT	27,500,381,792	33,000,381,792
FDRs held in USD	4,059,607,375	3,819,836,939
<b>Tk.</b>	<b>31,559,989,167</b>	<b>36,820,218,731</b>
<b>Tk.</b>	<b>57,752,836,503</b>	<b>52,013,459,742</b>
<b>10. Consolidated Fair Value Reserve: Tk. (167,909,431)</b>		
Opening Balance	(275,040,481)	734,507,296
Add: Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 29)	126,036,530	(1,139,696,255)
Less: Current Period/Year's Deferred Tax (Expense)/Income (Note - 29)	(18,905,480)	130,148,478
Closing Balance	(167,909,431)	(275,040,481)
<b>Tk.</b>	<b>(167,909,431)</b>	<b>(275,040,481)</b>

	31 Dec 2024	30 Jun 2024
<b>11. Consolidated Tax Holiday Reserve: Tk. 1,674,592,803</b>		
Opening Balance	951,511,612	133,398,880
Add: Transferred from Retained Earnings (Note - 13)	723,081,191	818,112,732
Closing Balance	<b>1,674,592,803</b>	<b>951,511,612</b>
<b>12. Consolidated Translation Reserve: Tk. 124,606,724</b>		
Opening Balance	97,906,017.00	(16,905,546)
Translation Adjustment for the Period/Year	26,700,707.00	114,811,563
Closing Balance	<b>124,606,724.00</b>	<b>97,906,017</b>
<b>13. Consolidated Retained Earnings: Tk. 116,359,875,096</b>		
Opening Balance	114,139,071,906	103,339,085,459
Add: Net Profit attributable to Equity Holders	12,694,845,491	20,925,834,784
Less: Transferred to Tax Holiday Reserve (Note - 11)	(723,081,191)	(818,112,732)
Less: Cash Dividend	(9,750,961,110)	(9,307,735,605)
Closing Balance	<b>116,359,875,096</b>	<b>114,139,071,906</b>
<b>14. Non Controlling Interest: Tk. 3,870,404</b>		
Opening Balance	2,318,478.00	709,376.00
Add: Net Profit attributable to Non Controlling Interest	1,557,567.00	1,611,137.00
Add: Unrealised Gain/(Loss) on Marketable Securities	(5,641.00)	(2,035.00)
Closing Balance	<b>3,870,404.00</b>	<b>2,318,478.00</b>
<b>15. Consolidated Loans and Borrowings: Tk. 1,130,659,370</b>		
Term Loan - Non Current Portion (Note - 15.1)	510,219,792	814,539,826
Term Loan - Current Portion (Note - 15.2)	620,439,578	614,539,826
	<b>1,130,659,370</b>	<b>1,429,079,652</b>
<b>15.1 Term Loan - Non Current Portion: Tk. 510,219,792</b>		
a) Standard Chartered Bank, Kenya	110,219,792	214,539,826
b) Standard Chartered Bank, Bangladesh	400,000,000	600,000,000
	<b>510,219,792</b>	<b>814,539,826</b>
<b>15.2 Term Loan - Current Portion: Tk. 620,439,578</b>		
a) Standard Chartered Bank, Kenya	220,439,578	214,539,826
b) Standard Chartered Bank, Bangladesh	400,000,000	400,000,000
	<b>620,439,578</b>	<b>614,539,826</b>
<b>16. Consolidated Deferred Tax Liabilities: Tk. 569,086,141</b>		
Deferred Tax - Property, Plant and Equipment:		
a) Square Pharmaceuticals PLC. (Note-16.1a)	612,920,573	673,568,392
b) Square Lifesciences Ltd. (Note-16.1b)	(14,202,001)	(5,949,954)
	598,718,572	667,618,439
Deferred Tax - Marketable Securities (Note-16.2)	(29,632,431)	(48,536,915)
	<b>569,086,141</b>	<b>619,081,524</b>
<b>16.1 Deferred Tax - Property, Plant and Equipment:</b>		
<b>a) Square Pharmaceuticals PLC.: Tk. 612,920,573</b>		
Carrying Amount	12,059,773,395	12,418,606,865
Tax Base	9,335,681,959	9,424,969,566
Taxable/(Deductible) Temporary Difference	2,724,091,436	2,993,637,299
Tax Rate	22.50%	22.50%
Closing Liabilities	612,920,573	673,568,392
Opening Liabilities	(673,568,392)	(944,474,683)
Current Period/Year's Expense/(Income)	<b>(60,647,819)</b>	<b>(270,906,291)</b>
<b>b) Square Lifesciences Ltd.: Tk. (14,202,001)</b>		
Carrying Amount	2,507,573,257	2,644,054,308
Tax Base	2,765,791,451	2,860,416,259
Taxable/(Deductible) Temporary Difference	(258,218,194)	(216,361,951)
Tax Rate	5.50%	2.75%
Closing Liabilities	(14,202,001)	(5,949,954)
Opening Liabilities	5,949,954	3,932,825
Current Period/Year's Expense/(Income)	<b>(8,252,047)</b>	<b>(2,017,129)</b>
* Property, plant and equipment excluding Lands, PPE in transit and assets under construction.		
<b>16.2 Deferred Tax - Marketable Securities: Tk. (29,632,431)</b>		
Carrying Amount	9,830,546,374	9,292,402,647
Tax Base	10,028,095,912	9,615,982,078
Taxable/(Deductible) Temporary Difference	(197,549,538)	(323,579,431)
Tax Rate	15.00%	15.00%
Closing Liabilities	(29,632,431)	(48,536,915)
Opening Liabilities	(48,536,915)	(81,611,922)
Current Period/Year's Expense/(Income)	<b>(78,169,346)</b>	<b>(130,148,837)</b>
<b>17. Consolidated Other Payables: Tk. 11,822,935,739</b>		
Sundry Creditors	633,983,548	539,395,363
Income Tax (Deduction at Source)	73,662,872	41,974,116
Retention Money	50,493,658	50,300,089
Dividend Payable	9,750,961,110	-
Workers' Profit Participation Fund and Welfare Fund	1,289,772,051	1,160,126,879
Interest Payable	24,062,500	29,147,526
	<b>11,822,935,739</b>	<b>1,820,943,973</b>
<b>18. Consolidated Current Tax Liabilities: Tk. 1,274,954,392</b>		
Opening balance	912,265,905	356,095,553
Provision for the Period/Year	2,424,802,712	4,661,815,173
Tax Paid (including Advance Income Tax) during the Period/Year	(2,062,114,225)	(4,105,644,821)
	<b>1,274,954,392</b>	<b>912,265,905</b>
<b>19. Consolidated Accrued Expenses: Tk. 261,226,667</b>		
Accrued Expenses	261,226,667	285,502,944
Audit Fees	100,000	1,290,329
	<b>261,226,667</b>	<b>286,793,273</b>



	<u>July'24 - Dec'24</u>	<u>July'23 - Dec'23</u>
<b>20. Consolidated Net Revenue: Tk. 37,717,778,672</b>		
Square Pharmaceuticals PLC. (Note - 20.1)	29,813,582,142	31,033,879,297
Square Lifesciences Ltd. (Note - 20.2)	7,603,042,538	4,456,288,766
Square Pharmaceuticals Kenya EPZ Ltd.	301,153,992	62,335,530
<b>Tk.</b>	<b><u>37,717,778,672</u></b>	<b><u>35,552,503,593</u></b>
<b>20.1 Square Pharmaceuticals PLC.: Tk. 29,813,582,142</b>		
<b>Local:</b>		
Gross Revenue	33,911,148,340	36,293,651,905
Value Added Tax	(4,378,353,682)	(5,256,967,590)
<b>Revenue without VAT</b>	<b>29,532,794,658</b>	<b>31,036,684,315</b>
Discount	(1,112,071,225)	(1,173,029,422)
<b>Net Revenue - Local</b>	<b>28,420,723,433</b>	<b>29,863,654,893</b>
Export Revenue - Equivalent to US \$11,661,087 (Jul'23-Dec'23: US \$11,525,880)	1,392,858,710	1,170,224,404
<b>Tk.</b>	<b><u>29,813,582,142</u></b>	<b><u>31,033,879,297</u></b>
<b>20.2 Square Lifesciences Ltd.: Tk. 7,603,042,538</b>		
<b>Local:</b>		
Gross Revenue	9,451,191,757	5,524,567,855
Value Added Tax	(1,409,472,442)	(818,651,445)
<b>Revenue without VAT</b>	<b>8,041,719,315</b>	<b>4,705,916,410</b>
Discount	(451,195,597)	(252,616,817)
<b>Net Revenue - Local</b>	<b>7,590,523,718</b>	<b>4,453,299,593</b>
Export Revenue - Equivalent to US \$105,155 (Jul'23-Dec'23: US \$27,468)	12,518,820	2,989,173
<b>Tk.</b>	<b><u>7,603,042,538</u></b>	<b><u>4,456,288,766</u></b>
<b>21. Consolidated Cost of Goods Sold: Tk. 19,893,431,304</b>		
Raw Materials Consumed (Note - 21.1)	9,185,208,744	8,135,298,387
Packing Materials Consumed (Note - 21.2)	4,587,058,592	3,833,404,290
<b>Cost of Materials Consumed</b>	<b>13,772,267,336</b>	<b>11,968,702,677</b>
Add: Manufacturing Overhead (Note - 21.3)	5,557,998,552	4,692,912,189
<b>Total Manufacturing Cost</b>	<b>19,330,265,888</b>	<b>16,661,614,866</b>
Add: Opening Work-in-Process	784,057,550	643,978,545
Less: Closing Work-in-Process	(940,413,948)	(706,539,938)
<b>Cost of Goods Manufactured</b>	<b>19,173,909,490</b>	<b>16,599,053,473</b>
Add: Opening Finished Goods	3,825,932,863	3,596,262,767
Add: Purchase of Finished Goods	1,937,318,643	1,736,673,630
Less: Cost of Physician Sample	(142,105,258)	(112,724,181)
<b>Cost of Goods Available for Sale</b>	<b>24,795,055,738</b>	<b>21,819,265,689</b>
Less: Closing Finished Goods	(4,901,624,434)	(3,734,303,608)
<b>Tk.</b>	<b><u>19,893,431,304</u></b>	<b><u>18,084,962,081</u></b>
<b>21.1 Consolidated Raw Materials Consumed: Tk. 9,185,208,744</b>		
Opening Stock	4,801,972,525	4,784,438,787
Purchase during the Period	9,838,352,155	7,961,295,529
Closing Stock	(5,455,115,936)	(4,610,435,929)
<b>Tk.</b>	<b><u>9,185,208,744</u></b>	<b><u>8,135,298,387</u></b>
<b>21.2 Consolidated Packing Materials Consumed: Tk. 4,587,058,592</b>		
Opening Stock	1,272,032,952	1,437,690,908
Purchase during the Period	5,008,695,021	3,660,336,051
Closing Stock	(1,693,669,381)	(1,264,622,669)
<b>Tk.</b>	<b><u>4,587,058,592</u></b>	<b><u>3,833,404,290</u></b>
<b>21.3 Consolidated Manufacturing Overhead: Tk. 5,557,998,552</b>		
Salaries & Allowances	1,717,327,815	1,413,625,782
Contribution to Provident Fund	50,425,732	31,678,309
Entertainment, Staff Lunch & Refreshments	97,210,332	77,773,815
Training & Development	636,753	356,224
Staff Uniform	68,417,875	63,996,935
Travelling & Conveyance	34,395,656	27,289,259
US FDA User Fees	82,628,520	73,149,378
Laboratory Consumables	413,135,902	364,716,854
Research and Product Development	192,012,460	64,987,466
Printing & Stationery	48,798,252	47,295,178
Courier, Telephone, Cell phone & Internet	5,143,423	5,028,516
Rental Expenses	5,556,495	605,110
Utilities Expense	736,655,557	667,587,404
Sanitation Expenses	125,497,349	78,953,156
Petrol, Oil & Lubricants	223,087,824	107,273,899
Generator Rental Expenses	18,000,000	7,300,000
Repairs & Maintenance - Factory	636,507,031	554,717,406
Repairs & Maintenance - Vehicle	61,171,837	57,262,452
Insurance Premium	30,695,479	24,524,534
Security Services	41,990,553	31,975,427
Govt. Taxes & License Fees	15,800,254	16,834,811
Toll Charges	81,819,230	36,412,074
Software, Hardware Support & VSAT Services	33,653,217	27,135,809
Depreciation	836,122,804	912,174,720
Other Expenses	1,308,202	257,671
<b>Tk.</b>	<b><u>5,557,998,552</u></b>	<b><u>4,692,912,189</u></b>

	<u>July'24 - Dec'24</u>	<u>July'23 - Dec'23</u>
<b>22. Consolidated Selling and Distribution Expenses: Tk. 6,045,429,884</b>		
Salaries & Allowances	946,381,969	838,583,397
Contribution to Provident Fund	78,042,481	60,994,263
Entertainment, Staff Lunch & Refreshments	22,240,509	15,339,082
Training & Development	5,838,983	4,956,575
Staff Uniform	3,518,860	3,173,253
Travelling & Conveyance	89,216,063	86,468,101
Printing & Stationery	49,425,366	43,723,162
Courier, Telephone, Cell phone & Internet	49,894,682	40,969,944
Office and Godown Rent	18,981,083	16,581,826
Utilities Expense	25,531,125	22,245,556
Sanitation Expenses	10,897,599	10,313,091
Field Staff Salaries, Allowances, TA & DA	1,984,655,468	1,817,318,112
Target Incentive to Field Staff	243,752,482	252,665,874
Promotional Expenses	563,300,475	516,819,052
Marketing Expenses	607,188,114	335,496,810
Pharmacovigilance	34,073,829	49,495,956
Marketing Website Platform Software Maintenance	7,535,633	5,651,840
Event, Programs and Conference	146,957,044	172,064,370
Literature and Publications	88,184,557	108,021,022
Market Research & Survey Expenses	12,661,447	9,247,561
Advertisement	756,000	130,000
Delivery & Packing Expenses	157,344,848	136,289,408
Export Expenses	166,430,399	85,605,851
Repairs & Maintenance - Office	35,899,902	32,919,121
Repairs & Maintenance - Vehicle	302,250,877	273,765,181
Insurance Premium	3,162,593	2,939,048
Security Services	56,537,996	47,617,220
Govt. Taxes & License Fees	26,519,661	18,327,656
Bank Charges	8,181,733	8,708,194
Software, Hardware Support & VSAT Services	37,763,617	26,517,737
Depreciation	113,389,371	114,963,266
Other Expenses	148,915,118	112,921,492
<b>Tk.</b>	<b><u>6,045,429,884</u></b>	<b><u>5,270,833,021</u></b>
<b>23. Consolidated Administrative Expenses: Tk. 884,315,155</b>		
Salaries & Allowances	292,382,742	262,263,484
Contribution to Provident Fund	7,482,640	5,954,709
Directors' Remuneration	44,437,500	44,437,500
Entertainment, Staff Lunch & Refreshments	39,045,477	35,589,139
Training & Development	3,288,068	3,019,293
Staff Uniform	904,725	851,579
Travelling & Conveyance	90,163,957	80,098,529
Printing & Stationery	10,642,980	9,844,967
Courier, Telephone, Cell phone & Internet	6,628,549	5,004,918
Office Rent	14,341,364	10,172,688
Utilities Expense	16,995,909	14,075,250
Sanitation Expenses	5,588,248	4,769,009
Subscription and Donation	2,615,200	2,435,000
Legal & Professional Fees	4,006,439	1,704,081
Repairs & Maintenance - Office	103,570,053	89,162,270
Repairs & Maintenance - Vehicle	43,819,490	44,754,375
Insurance Premium	14,562,520	15,848,694
Security Services	33,670,507	27,013,780
Govt. Taxes & License Fees	15,390,161	38,232,093
Bank Charges	3,702,559	5,364,674
Software & Hardware Support Services	4,469,501	5,355,675
Depreciation	120,432,032	114,571,004
Other Expenses	6,174,534	9,306,596
<b>Tk.</b>	<b><u>884,315,155</u></b>	<b><u>829,829,307</u></b>
<b>24. Consolidated Finance Cost: Tk. 127,200,832</b>		
Square Pharmaceuticals PLC.	6,203	16,325
Square Lifesciences Ltd.	50,891,574	57,089,527
Square Pharmaceuticals Kenya EPZ Ltd.	76,303,055	42,563,227
<b>Tk.</b>	<b><u>127,200,832</u></b>	<b><u>99,669,079</u></b>
<b>25. Consolidated Other Operating Income: Tk. 227,776,534</b>		
Rental Income	987,708	876,706
Sale of Scrap	30,972,838	26,181,401
Gain on Fluctuation of Foreign Currency	183,778,097	78,183,399
Cash Incentive Received against Export	2,417,200	22,924,800
P.F Forfeiture Amount	934,049	261,253
Gain/(Loss) on Disposal of Property, Plant and Equipment	8,686,642	-
<b>Tk.</b>	<b><u>227,776,534</u></b>	<b><u>128,427,559</u></b>
<b>26. Consolidated Income from Investments: Tk. 3,056,110,856</b>		
Interest from Deposits	1,810,992,019	1,472,360,382
Interest from Short Notice Deposits	671,593,561	407,895,069
Gain on Redemption of Zero Coupon Bond	17,688,683	34,547,098
Interest from Subordinate Bonds	335,079,562	207,217,424
Dividend Income	127,564,112	14,816,295
Gain on Marketable Securities (Realized)	93,192,919	852,558
<b>Tk.</b>	<b><u>3,056,110,856</u></b>	<b><u>2,137,688,825</u></b>
<b>27. Consolidated Allocation for WPPF &amp; WF: Tk. 665,805,097</b>		
Square Pharmaceuticals PLC.	500,933,068	590,332,841
Square Lifesciences Ltd.	164,872,029	61,851,512
<b>Tk.</b>	<b><u>665,805,097</u></b>	<b><u>652,184,353</u></b>

	July'24 - Dec'24	July'23 - Dec'23
<b>28. Consolidated Income Tax Expense: Tk. 2,355,902,846</b>		
<b>Current Tax Expense:</b>		
Square Pharmaceuticals PLC.	2,234,244,820	2,526,922,772
Square Lifesciences Ltd.	190,557,892	38,752,658
	<u>2,424,802,712</u>	<u>2,565,675,430</u>
<b>Deferred Tax Expense/(Income):</b>		
Square Pharmaceuticals PLC.	(60,647,819)	83,766,623
Square Lifesciences Ltd.	(8,252,047)	(1,641,751)
	<u>(68,899,866)</u>	<u>82,124,872</u>
<b>Tk.</b>	<u><b>2,355,902,846</b></u>	<u><b>2,647,800,302</b></u>
<b>29. Consolidated Unrealised Gain/(Loss) on Marketable Securities: Tk. 107,125,409</b>		
Closing Unrealised Gain/(Loss)	(174,700,135)	817,579,300
Less: Opening Unrealised Gain/(Loss)	(300,730,028)	816,119,218
	<u>126,029,893</u>	<u>1,460,082</u>
Less: Related Deferred Tax	(18,904,484)	(146,008)
	<u>107,125,409</u>	<u>1,314,074</u>
<b>Tk.</b>	<u><b>107,125,409</b></u>	<u><b>1,314,074</b></u>
<b>30. Consolidated Net Asset Value (NAV) per Share: Tk. 145.52</b>		
Net Asset attributable to the Ordinary Shareholders	128,997,018,492	125,919,302,354
Number of Shares outstanding	886,451,010	886,451,010
Net Asset Value (NAV) per Share	<u>145.52</u>	<u>142.05</u>
<b>Tk.</b>	<u><b>145.52</b></u>	<u><b>142.05</b></u>
<b>31. Consolidated Earnings per Share (EPS): Tk. 14.32</b>		
Profit for the Period	12,696,403,058	11,245,960,629
Number of Shares outstanding	886,451,010	886,451,010
Earnings per Share (EPS)	<u>14.32</u>	<u>12.69</u>
<b>Tk.</b>	<u><b>14.32</b></u>	<u><b>12.69</b></u>
<b>32. Consolidated Net Operating Cash Flow (NOCF) per Share: Tk. 8.28</b>		
Net Cash Generated from Operating Activities (Note - 32.1)	7,335,508,748	12,740,580,021
Number of Shares outstanding	886,451,010	886,451,010
Net Operating Cash Flow (NOCF) per Share	<u>8.28</u>	<u>14.37</u>
<b>Tk.</b>	<u><b>8.28</b></u>	<u><b>14.37</b></u>
Due to Eid holiday in June 2023, additional credit facility were provided to the local customers which were collected during July'23 - Dec'23. Additionally, the Company received Insurance claim against the fire incident of LVP. These two factors caused a spike in the NOCF per share in July'23- Dec'23. There is no such factors in this period. Therefore, the NOCF per share seen a decline in the current period.		
<b>32.1 Consolidated Reconciliation of Net Profit with Net Cash Generated from Operating Activities:</b>		
<b>Profit for the Period</b>	<b>12,696,403,058</b>	<b>11,245,960,629</b>
Adjustments for:		
Non-Cash Income/Expenses:		
Depreciation	1,069,944,207	1,141,708,990
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents	(210,478,803)	226,201
Profit from Associate Undertakings	(1,666,822,114)	(1,012,618,795)
Translation Adjustments	26,700,706	(62,349,088)
Deferred Tax (Expense) / Income	(68,899,866)	82,124,872
	<u>(849,555,870)</u>	<u>149,092,180</u>
Non-Operating Income/Expenses:		
Income from Investments (Note - 26)	(3,056,110,856)	(2,137,688,825)
Gain/(Loss) on Disposal of Property, Plant and Equipment (Note - 25)	(8,686,642)	-
	<u>(3,064,797,498)</u>	<u>(2,137,688,825)</u>
Changes in Working Capital:		
(Increase)/Decrease in Inventories	(2,010,164,093)	(32,901,685)
(Increase)/Decrease in Trade Receivables	(16,834,156)	581,132,314
(Increase)/Decrease in Other Receivables	(89,127)	961,655,427
(Increase)/Decrease in Advances, Deposits and Prepayments	122,401,204	(1,257,096,192)
Increase/(Decrease) in Trade Payables	(130,007,307)	2,381,678,885
Increase/(Decrease) in Other Payables	251,030,656	8,614,000
Increase/(Decrease) in Current Tax Liabilities	362,688,487	689,370,288
Increase/(Decrease) in Accrued Expenses	(25,566,606)	150,763,002
	<u>(1,446,540,942)</u>	<u>3,483,216,037</u>
<b>Net Cash from Operating Activities</b>	<u><b>7,335,508,748</b></u>	<u><b>12,740,580,021</b></u>
<b>Tk.</b>	<u><b>7,335,508,748</b></u>	<u><b>12,740,580,021</b></u>
<b>33. Consolidated Contingent Liabilities:</b>		
Liabilities for at Sight Letter of Credit as of 31 December 2024:		
a) Square Pharmaceuticals PLC.: Tk. Tk. 7,283,395,575.		
b) Square Lifesciences Ltd.: Tk. 201,805,272.		
<b>34. Related Party Transactions:</b>		
<b>A. Associates:</b>		
<b>Square Textiles PLC. (46.36% share):</b>		
Opening Balance	-	-
Addition during the Period	5,386,200,000	3,217,925,000
Realized during the Period	(5,386,200,000)	(1,738,773,000)
Closing Balance	<u>-</u>	<u>1,479,152,000</u>
<b>Tk.</b>	<u><b>-</b></u>	<u><b>1,479,152,000</b></u>
<b>Square Fashions Ltd. (48.63% share):</b>		
Opening Balance	-	-
Addition during the Period	11,975,938,570	3,420,675,220
Realized during the Period	(11,975,938,570)	(3,461,324,042)
Closing Balance	<u>-</u>	<u>(40,648,822)</u>
<b>Tk.</b>	<u><b>-</b></u>	<u><b>(40,648,822)</b></u>
<b>Square Hospitals Ltd. (49.94% Shares):</b>		
Opening Balance	-	-
Addition during the Period	22,759,766	19,156,379
Paid during the Period	(22,753,808)	(19,156,379)
Closing Balance (Payable)	<u>5,958</u>	<u>-</u>
<b>Tk.</b>	<u><b>5,958</b></u>	<u><b>-</b></u>

	<u>July'24 - Dec'24</u>	<u>July'23 - Dec'23</u>
<b>B. Subsidiaries of Associates:</b>		
<b>Square Denims Ltd. (Subsidiary of Square Fashions Ltd.):</b>		
Opening Balance	-	-
Addition during the Period	840,702,503	842,621,288
Realized during the Period	(840,702,503)	(842,621,288)
Closing Balance	<u>-</u>	<u>-</u>
<b>Tk.</b>	<u>-</u>	<u>-</u>
<b>Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.):</b>		
Opening Balance	-	-
Addition during the Period	282,037,035	1,020,364,484
Realized during the Period	(282,037,035)	(1,020,364,484)
Closing Balance	<u>-</u>	<u>-</u>
<b>Tk.</b>	<u>-</u>	<u>-</u>
<b>C. Others:</b>		
<b>Square InformatiX Ltd. (Service Provider):</b>		
Opening Balance	-	-
Addition during the Period	97,160,495	72,613,109
Paid during the Period	(97,120,666)	(72,613,109)
Closing Balance (Payable)	<u>39,829</u>	<u>-</u>
<b>Tk.</b>	<u>39,829</u>	<u>-</u>
<b>Square Toiletries Ltd. (Supplier):</b>		
Opening Balance	-	-
Addition during the Period	87,297,553	63,409,150
Paid during the Period	(87,281,025)	(63,409,150)
Closing Balance (Payable)	<u>16,528</u>	<u>-</u>
<b>Tk.</b>	<u>16,528</u>	<u>-</u>
<b>Square Food &amp; Beverages Ltd. (Supplier):</b>		
Opening Balance	-	-
Addition during the Period	81,591,004	51,285,349
Paid during the Period	(81,591,004)	(51,285,349)
Closing Balance (Payable)	<u>-</u>	<u>-</u>
<b>Tk.</b>	<u>-</u>	<u>-</u>
<b>Square Securities Management Ltd. (Port Folio Management):</b>		
Opening Balance	10,659,741	121,108,758
Addition during the Period	515,198,609	3,359,689,996
Realized during the Period	(479,032,337)	(3,352,506,481)
Closing Balance	<u>46,826,013</u>	<u>128,292,273</u>
<b>Tk.</b>	<u>46,826,013</u>	<u>128,292,273</u>
<b>Pharma Packages (Pvt.) Ltd. (Supplier):</b>		
Opening Balance	99,484,237	23,321,437
Addition during the Period	226,436,116	1,315,479,070
Paid during the Period	(307,596,953)	(868,998,152)
Closing Balance (Payable)	<u>18,323,400</u>	<u>469,802,355</u>
<b>Tk.</b>	<u>18,323,400</u>	<u>469,802,355</u>
<b>AEGIS Services Ltd. (Service Provider):</b>		
Opening Balance	258,720	1,097,545
Addition during the Period	243,158,860	168,882,966
Paid during the Period	(243,417,580)	(169,980,511)
Closing Balance (Payable)	<u>-</u>	<u>-</u>
<b>Tk.</b>	<u>-</u>	<u>-</u>



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Statement of Financial Position

As at 31 December 2024

Particulars	Notes	31 Dec 2024	30 Jun 2024
		Taka	Taka
<b>ASSETS</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	02	26,067,414,111	23,655,156,304
Investment in Subsidiaries and Associates	03	2,624,852,483	2,624,852,483
Investment in Marketable Securities	04	9,497,520,669	9,001,712,647
Long Term Investment - Others	05	7,532,309,610	6,992,206,904
		<b>45,722,096,873</b>	<b>42,273,928,338</b>
<b>Current Assets:</b>			
Inventories	06	11,813,277,445	10,732,803,469
Trade and Other Receivables	07	5,093,295,100	4,754,218,234
Advances, Deposits and Prepayments	08	1,706,649,299	1,943,361,351
Cash and Cash Equivalents	09	57,959,907,771	52,305,603,356
		<b>76,573,129,615</b>	<b>69,735,986,410</b>
<b>TOTAL ASSETS</b>		<b>122,295,226,488</b>	<b>112,009,914,748</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY:</b>			
Share Capital	10	8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
General Reserve		105,878,200	105,878,200
Fair Value Reserve	11	(152,564,188)	(270,973,443)
Retained Earnings	12	93,154,343,002	95,060,239,763
<b>TOTAL EQUITY</b>		<b>104,007,632,114</b>	<b>105,795,119,620</b>
<b>LIABILITIES:</b>			
<b>Non-Current Liabilities:</b>			
Deferred Tax Liabilities	13	585,997,481	625,749,549
		<b>585,997,481</b>	<b>625,749,549</b>
<b>Current Liabilities:</b>			
Trade Payables		510,729,170	686,238,794
Other Payables	14	15,564,534,564	3,512,907,803
Current Tax Liabilities	15	1,179,910,862	912,265,905
Accrued Expenses	16	260,310,524	285,649,448
Unclaimed Dividend	17	186,111,773	191,983,629
		<b>17,701,596,893</b>	<b>5,589,045,579</b>
<b>TOTAL LIABILITIES</b>		<b>18,287,594,374</b>	<b>6,214,795,128</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>122,295,226,488</b>	<b>112,009,914,748</b>
<b>Net Assets Value (NAV) per Share</b>	26	<b>117.33</b>	<b>119.35</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary

**Statement of Profit or Loss and Other Comprehensive Income**  
**For the Quarter Ended 31 December 2024**

Particulars	Notes	Six-Month Result		2nd Quarter Result	
		July'24 - Dec'24	July'23 - Dec'23	Oct'24 - Dec'24	Oct'23 - Dec'23
		Taka	Taka	Taka	Taka
<b>Net Revenue</b>	18	<b>29,896,175,660</b>	<b>31,033,879,297</b>	<b>15,879,308,873</b>	<b>15,380,162,465</b>
Cost of Goods Sold	19	(17,308,352,978)	(15,732,754,009)	(9,728,323,206)	(8,119,429,613)
<b>Gross Profit</b>		<b>12,587,822,682</b>	<b>15,301,125,288</b>	<b>6,150,985,667</b>	<b>7,260,732,852</b>
Selling and Distribution Expenses	20	(5,954,028,247)	(5,238,111,767)	(2,936,614,000)	(2,769,613,383)
Administrative Expenses	21	(881,733,530)	(820,280,584)	(443,428,396)	(455,353,040)
Finance Cost		(6,203)	(16,325)	(6,203)	(16,325)
<b>Operating Expenses</b>		<b>(6,835,767,980)</b>	<b>(6,058,408,676)</b>	<b>(3,380,048,599)</b>	<b>(3,224,982,748)</b>
<b>Profit before Other Operating Income</b>		<b>5,752,054,702</b>	<b>9,242,716,612</b>	<b>2,770,937,068</b>	<b>4,035,750,104</b>
Other Operating Income	22	1,713,803,860	1,016,584,218	798,650,467	476,890,473
<b>Profit from Operations</b>		<b>7,465,858,562</b>	<b>10,259,300,830</b>	<b>3,569,587,535</b>	<b>4,512,640,577</b>
Income from Investments	23	3,053,735,856	2,137,688,825	1,589,515,211	1,050,282,114
<b>Profit before contribution to WPPF &amp; WWF</b>		<b>10,519,594,418</b>	<b>12,396,989,655</b>	<b>5,159,102,746</b>	<b>5,562,922,691</b>
Contribution to WPPF & WWF		(500,933,068)	(590,332,841)	(245,671,560)	(264,901,081)
<b>Profit before Tax</b>		<b>10,018,661,350</b>	<b>11,806,656,814</b>	<b>4,913,431,186</b>	<b>5,298,021,610</b>
Current Tax (Expense)		(2,234,244,820)	(2,526,922,772)	(1,115,747,951)	(1,042,991,071)
Deferred Tax (Expense) / Income		60,647,819	(83,766,623)	28,290,151	(127,821,288)
<b>Income Tax Expense</b>	24	<b>(2,173,597,001)</b>	<b>(2,610,689,395)</b>	<b>(1,087,457,800)</b>	<b>(1,170,812,359)</b>
<b>Profit after Tax</b>		<b>7,845,064,349</b>	<b>9,195,967,419</b>	<b>3,825,973,386</b>	<b>4,127,209,251</b>
Unrealised Gain/(Loss) on Marketable Securities	25	139,305,006	1,849,750	(692,655,629)	(95,856,195)
Deferred Tax (Expense) / Income	13.2	(20,895,751)	(184,975)	103,898,344	9,585,619
<b>Other Comprehensive Income</b>		<b>118,409,255</b>	<b>1,664,775</b>	<b>(588,757,285)</b>	<b>(86,270,576)</b>
<b>Total Comprehensive Income</b>		<b>7,963,473,604</b>	<b>9,197,632,194</b>	<b>3,237,216,101</b>	<b>4,040,938,676</b>
<b>Earnings per Share (EPS)</b>	27	<b>8.85</b>	<b>10.37</b>	<b>4.32</b>	<b>4.66</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Statement of Changes in Equity For the Quarter Ended 31 December 2024

Particulars	Share Capital Taka	Share Premium Taka	General Reserve Taka	Fair Value Reserve Taka	Retained Earnings Taka	Total Taka
<b>As At 01 July 2023</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>734,507,296</b>	<b>88,776,603,462</b>	<b>100,516,964,058</b>
Profit after Tax	-	-	-	-	9,195,967,419	9,195,967,419
Other Comprehensive Income	-	-	-	1,664,775	-	1,664,775
Cash Dividend (2022-23)	-	-	-	-	(9,307,735,605)	(9,307,735,605)
<b>As At 31 December 2023</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>736,172,071</b>	<b>88,664,835,276</b>	<b>100,406,860,647</b>
<b>As At 01 July 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(270,973,443)</b>	<b>95,060,239,763</b>	<b>105,795,119,620</b>
Profit after Tax	-	-	-	-	7,845,064,349	7,845,064,349
Other Comprehensive Income	-	-	-	118,409,255	-	118,409,255
Cash Dividend (2023-24)	-	-	-	-	(9,750,961,110)	(9,750,961,110)
<b>As At 31 December 2024</b>	<b>8,864,510,100</b>	<b>2,035,465,000</b>	<b>105,878,200</b>	<b>(152,564,188)</b>	<b>93,154,343,002</b>	<b>104,007,632,114</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary



# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Statement of Cash Flows For the Quarter Ended 31 December 2024

Particulars	Notes	July'24 - Dec'24	July'23 - Dec'23
		Taka	Taka
<b>Cash Flows from Operating Activities:</b>			
Receipts from Customers		34,062,799,865	36,837,984,047
Receipts from Others		1,520,557,780	1,192,826,206
Payments to Suppliers		(13,608,261,896)	(9,924,362,115)
Payments for Manufacturing and Operating Expenses		(10,951,660,475)	(9,509,486,927)
Payment of Value Added Tax		(4,320,367,894)	(4,769,822,196)
<b>Cash Generated from Operations</b>		<b>6,703,067,380</b>	<b>13,827,139,016</b>
Interest Paid		(6,203)	(16,325)
Payment of Income Tax		(1,766,599,863)	(1,868,199,781)
Payment of WPPF & WF		(536,159,925)	(575,771,720)
Others		2,257,179,456	916,953,857
<b>Net Cash from Operating Activities</b>		<b>6,657,480,845</b>	<b>12,300,105,047</b>
<b>Cash Flows from Investing Activities:</b>			
Purchase of Property, Plant and Equipment		(3,233,956,113)	(835,127,087)
Proceeds from Sale of Property, Plant and Equipment		22,309,355	-
Long Term Investment - Others		(540,102,706)	(1,939,594,992)
Investment in Marketable Securities		(263,310,097)	(3,728,491,944)
Interest Received		2,708,416,424	1,762,743,936
Dividends Received	23	125,189,112	14,816,295
<b>Net Cash from/(Used in) Investing Activities</b>		<b>(1,181,454,025)</b>	<b>(4,725,653,792)</b>
<b>Cash Flows from Financing Activities:</b>			
Payment of Dividend		(5,871,856)	(8,508,143)
<b>Net Cash Used in Financing Activities</b>		<b>(5,871,856)</b>	<b>(8,508,143)</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>		<b>5,470,154,964</b>	<b>7,565,943,112</b>
Cash and Cash Equivalents at 01 July	09	52,305,603,356	50,079,192,249
Effect of Exchange Rate Fluctuations on Cash and Cash Equivalents		184,149,451	78,264,044
<b>Cash and Cash Equivalents at 31 December</b>	09	<b>57,959,907,771</b>	<b>57,723,399,404</b>
<b>Net Operating Cash Flow (NOCF) per Share</b>	28	<b>7.51</b>	<b>13.88</b>

The annexed notes form an integral part of these financial statements.

Sd/-  
Samuel S Chowdhury  
Chairman

Sd/-  
Mrs. Ratna Patra  
Vice-Chairman

Sd/-  
Tapan Chowdhury  
Managing Director

Sd/-  
Muhammad Zahangir Alam  
Chief Financial Officer

Sd/-  
Khandaker Habibuzzaman  
Company Secretary





# SQUARE PHARMACEUTICALS PLC.

AND ITS SUBSIDIARIES

## Notes to the Financial Statements For the Quarter Ended 31 December 2024

### 01. Basis of Preparation of the Interim Financial Statements:

These Financial Statements are the unaudited Interim Financial Statements of Square Pharmaceuticals PLC., a company incorporated in Bangladesh under Companies Act, 1913 for the 2nd Quarter ended on December 31, 2024. These are prepared in accordance with the International Accounting Standard (IAS-34) 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2024, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below, Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

We understand that our business is growing every year that means our assets are performing according to the intention of procurement and the discounted future cash flow from the operation of the assets would be positive if we disposed those assets at the date of financial reporting. But at present, we have no intention to dispose these assets. Therefore, it is not required to record the impairment gain as provisions of IAS-36.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

There is no significant event after the end of the interim period that has to be reflected in these financial statements for the interim period.

### 02. Property, Plant and Equipment: Tk. 26,067,414,111

#### Cost:

Opening Balance

31 Dec 2024 30 Jun 2024

Addition during the Period/Year

45,591,709,620 43,059,540,662

741,409,976 2,855,972,978

46,333,119,596 45,915,513,640

Disposal/Transfer during the Period/Year

(45,031,480) (323,804,020)

Tk. 46,288,088,116 45,591,709,620

#### Accumulated Depreciation:

Opening Balance

24,687,303,495 23,089,413,939

Charged for the Period/Year

801,112,993 1,728,738,883

25,488,416,488 24,818,152,822

Disposal/Transfer during the Period/Year

(31,408,767) (130,849,327)

Tk. 25,457,007,721 24,687,303,495

#### Net Book Value

Property, Plant and Equipment in Transit (Note - 02.1)

20,831,080,395 20,904,406,125

Building under Construction (Note - 02.2)

689,619,042 977,165,568

Written Down Value

4,546,714,674 1,773,584,611

Tk. 26,067,414,111 23,655,156,304

### 02.1 Property, Plant and Equipment in Transit: Tk. 689,619,042

Opening Balance

977,165,568 715,369,536

Addition during the Period/Year

366,432,699 937,119,275

1,343,598,267 1,652,488,811

Transfer during the Period/Year

(653,979,225) (675,323,243)

Tk. 689,619,042 977,165,568

### 02.2 Building under Construction: Tk. 4,546,714,674

Opening Balance

1,773,584,611 1,081,705,847

Addition during the Period/Year

2,773,130,063 1,063,055,568

4,546,714,674 2,144,761,415

Transfer during the Period/Year

(371,176,804)

Tk. 4,546,714,674 1,773,584,611

### 03. Investment in Subsidiaries and Associates: Tk. 2,624,852,483

#### 03.1 Subsidiaries: Tk. 2,037,772,688

(i) Square Pharmaceuticals Kenya EPZ Ltd. (8,000,000 Ordinary Shares plus Share Money Deposit)

985,742,688 985,742,688

(ii) Square Lifesciences Ltd., Bangladesh (9,995,000 Ordinary Shares)

999,500,000 999,500,000

(iii) Samson Pharma Inc., The Philippines (139,998 Ordinary Shares)

52,530,000 52,530,000

Tk. 2,037,772,688 2,037,772,688

#### 03.2 Associates: Tk. 587,079,795

(i) Square Textiles PLC. (91,436,677 Ordinary Shares of Tk. 10/- each including Bonus Shares)

225,129,795 225,129,795

(ii) Square Hospitals Ltd. (199,750 Ordinary Shares of Tk. 1,000/- each plus Share Premium)

210,750,000 210,750,000

(iii) Square Fashions Ltd. (462,000 Ordinary Shares of Tk. 100/- each plus Share Premium)

151,200,000 151,200,000

Tk. 587,079,795 587,079,795

Tk. 2,624,852,483 2,624,852,483

### 04. Investment in Marketable Securities: Tk. 9,497,520,669

#### 04.1 Cost:

Opening Balance

9,320,504,933 3,773,747,813

Addition during the Period/Year

473,508,707 5,649,171,398

Sold during the Period/Year

(117,005,691) (102,414,278)

Tk. 9,677,007,949 9,320,504,933

#### 04.2 Market Value:

Opening Balance

9,001,712,647 4,589,867,031

Addition during the Period/Year

706,006,632 4,524,172,652

Sold during the Period/Year

(210,198,610) (112,327,036)

Tk. 9,497,520,669 9,001,712,647

### 05. Long Term Investment - Others: Tk. 7,532,309,610

#### 05.1 Ordinary Shares (Unquoted): Tk. 127,694,430

(i) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)

12,000,000 12,000,000

(ii) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)

15,694,430 15,694,430

(iii) FAM - First Fixed Income Fund (1,000 Units of Tk. 100,000/- each)

100,000,000 100,000,000

Tk. 127,694,430 127,694,430

#### 05.2 Non-Convertible Subordinated Bonds: Tk. 7,100,000,000

(i) Mutual Trust Bank Ltd. (220 Bonds)

2,200,000,000 2,200,000,000

(ii) Southeast Bank Ltd. (3,000 Bonds)

300,000,000 400,000,000

(iii) Islami Bank Bangladesh Ltd. (30 Bonds)

300,000,000 400,000,000

(iv) Trust Bank Ltd. (30 Bonds)

300,000,000 400,000,000

(v) Eastern Bank Ltd. (50 Bonds)

500,000,000 500,000,000

(vi) Prime Bank Ltd. (100 Bonds)

1,000,000,000 1,000,000,000

(vii) Dutch Bangla Bank Ltd. (150 Bonds)

1,500,000,000 1,500,000,000

(viii) Shahjalal Islami Bank PLC. (1000 Bonds)

1,000,000,000 -

Tk. 7,100,000,000 6,400,000,000

#### 05.3 Non-Convertible Zero Coupon Bonds: Tk. 304,615,180

(i) LankaBangla Finance Ltd.

- 67,033,336

(ii) Brac Bank Ltd. (200 Bonds)

187,659,050 238,677,650

(iii) IDLC Finance Ltd. (240 Bonds)

116,956,130 158,801,488

Tk. 304,615,180 464,512,474

Tk. 7,532,309,610 6,992,206,904

	<u>31 Dec 2024</u>	<u>30 Jun 2024</u>
<b>06. Inventories: Tk. 11,813,277,445</b>		
Raw Materials	4,387,717,419	3,722,861,831
Packing Materials	1,328,322,168	1,091,402,281
Work-in-Process	669,632,733	582,783,730
Finished Goods	3,981,524,205	3,531,153,695
Spares & Accessories	1,154,734,000	951,053,588
Goods- in-Transit	291,346,920	853,548,344
<b>Tk.</b>	<b><u>11,813,277,445</u></b>	<b><u>10,732,803,469</u></b>
<b>07. Trade and Other Receivables: Tk. 5,093,295,100</b>		
Trade Receivables	2,772,082,943	2,560,353,465
Other Receivables (Note - 07.1)	2,321,212,157	2,193,864,769
<b>Tk.</b>	<b><u>5,093,295,100</u></b>	<b><u>4,754,218,234</u></b>
<b>07.1 Other Receivables: Tk. 2,321,212,157</b>		
Interest Receivable from Fixed Deposit Receipts	1,647,266,098	1,520,761,823
Interest Receivable from Short Notice Deposits	7,462,258	1,300
Gain against Zero Coupon Bonds (Receivable)	69,529,676	87,443,699
Interest Receivable from Subordinated Bonds	58,210,958	47,324,767
Accrued Income	308,743,168	308,333,181
Insurance Claim Receivable	230,000,000	230,000,000
<b>Tk.</b>	<b><u>2,321,212,157</u></b>	<b><u>2,193,864,769</u></b>
<b>08. Advances, Deposits and Prepayments: Tk. 1,706,649,299</b>		
<b>08.1 Advances: Tk. 995,627,329</b>		
Employees	288,035,467	283,810,814
Advance Income Tax	-	200,000,000
Land Purchase	91,044,000	84,081,400
Suppliers	616,547,862	576,405,123
<b>Tk.</b>	<b><u>995,627,329</u></b>	<b><u>1,144,297,337</u></b>
<b>08.2 Deposits: Tk. 654,850,168</b>		
Value Added Tax	231,482,461	289,468,249
Earnest Money & Security Deposit	388,090,845	402,702,619
Others	35,276,862	13,001,014
<b>Tk.</b>	<b><u>654,850,168</u></b>	<b><u>705,171,882</u></b>
<b>08.3 Prepayments: Tk. 56,171,802</b>		
Office Rent	22,852,440	23,242,440
Insurance Premium	33,319,362	70,649,692
<b>Tk.</b>	<b><u>56,171,802</u></b>	<b><u>93,892,132</u></b>
<b>Tk.</b>	<b><u>1,706,649,299</u></b>	<b><u>1,943,361,351</u></b>
<b>09. Cash and Cash Equivalents: Tk. 57,959,907,771</b>		
<b>09.1 Cash in Hand</b>		
<b>09.2 Cash at Bank:</b>		
Current Accounts	541,920,096	404,685,504
STD & SND Accounts	15,009,772,474	14,182,411,481
Export Retention Quota Accounts (held in USD)	174,542,008	174,360,222
Margin Held Accounts (held in USD)	585,118,343	525,205,243
Dividend Accounts (Note - 17)	9,937,105,686	191,983,630
<b>Tk.</b>	<b><u>26,248,458,606</u></b>	<b><u>15,478,646,080</u></b>
<b>09.3 Fixed Deposit Receipts (FDRs):</b>		
FDRs held in BDT	27,500,381,792	33,000,381,792
FDRs held in USD	4,059,607,375	3,819,836,939
<b>Tk.</b>	<b><u>31,559,989,167</u></b>	<b><u>36,820,218,731</u></b>
<b>Tk.</b>	<b><u>57,959,907,771</u></b>	<b><u>52,305,603,356</u></b>
<b>10. Share Capital: Tk. 8,864,510,100</b>		
<b>Authorised:</b>		
1,000,000,000 Ordinary Shares of Tk. 10/- each		
<b>Tk.</b>	<b><u>10,000,000,000</u></b>	<b><u>10,000,000,000</u></b>
<b>Paid-up:</b>		
<b>a) Issued for Cash:</b>		
10,092,300 Ordinary Shares of Tk. 10/- each fully paid-up in cash	100,923,000	100,923,000
<b>b) Issued for Consideration other than Cash:</b>		
40,020 Ordinary Shares of Tk. 10/- each fully paid-up for consideration other than cash	400,200	400,200
<b>c) Issued as Bonus Share:</b>		
876,318,690 Ordinary Shares of Tk. 10/- each fully paid-up as Bonus Shares	8,763,186,900	8,763,186,900
<b>Tk.</b>	<b><u>8,864,510,100</u></b>	<b><u>8,864,510,100</u></b>
<b>11. Fair Value Reserve: Tk. (152,564,188)</b>		
Opening Balance	(270,973,443)	734,507,296
Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 25)	139,305,006	(1,134,911,504)
Current Period's Deferred Tax (Expense)/Income (Note - 13.2)	(20,895,751)	129,430,765
<b>Tk.</b>	<b><u>(152,564,188)</u></b>	<b><u>(270,973,443)</u></b>
<b>12. Retained Earnings: Tk. 93,154,343,002</b>		
Opening Balance	95,060,239,763	88,776,603,462
Profit after Tax	7,845,064,349	15,591,371,906
Cash Dividend	(9,750,961,110)	(9,307,735,605)
<b>Tk.</b>	<b><u>93,154,343,002</u></b>	<b><u>95,060,239,763</u></b>
<b>13. Deferred Tax Liabilities: Tk. 585,997,481</b>		
Deferred Tax - Property, Plant and Equipment (Note - 13.1)	612,920,573	673,568,392
Deferred Tax - Marketable Securities (Note - 13.2)	(26,923,092)	(47,818,843)
<b>Tk.</b>	<b><u>585,997,481</u></b>	<b><u>625,749,549</u></b>
<b>13.1 Deferred Tax - Property, Plant and Equipment: Tk. 612,920,573</b>		
Carrying Amount	12,059,773,395	12,418,606,865
Tax Base	9,335,681,959	9,424,969,566
Taxable/(Deductible) Temporary Difference	2,724,091,436	2,993,637,299
Tax Rate	22.50%	22.50%
Closing Liability	612,920,573	673,568,392
Opening Liability	(673,568,392)	(944,474,683)
Current Period's Expense/(Income)	(60,647,819)	(270,906,291)
<b>Tk.</b>	<b><u>(60,647,819)</u></b>	<b><u>(270,906,291)</u></b>
* Property, plant and equipment excluding lands, PPE in transit and assets under construction.		
<b>13.2 Deferred Tax - Marketable Securities: Tk. (26,923,092)</b>		
Carrying Amount	9,497,520,669	9,001,712,647
Tax Base	9,677,007,949	9,320,504,933
Taxable/(Deductible) Temporary Difference	(179,487,280)	(318,792,286)
Tax Rate	15.00%	15.00%
Closing Liability	(26,923,092)	(47,818,843)
Opening Liability	47,818,843	(81,611,922)
Current Period's Expense/(Income)	20,895,751	(129,430,765)
<b>Tk.</b>	<b><u>20,895,751</u></b>	<b><u>(129,430,765)</u></b>

	<u>31 Dec 2024</u>	<u>30 Jun 2024</u>
<b>14. Other Payables: Tk. 15,564,534,564</b>		
Sundry Creditors	4,829,192,572	2,494,687,117
Income Tax (Deduction at Source)	15,018,771	13,630,694
Retention Money	10,196,815	10,197,839
Dividend Payable	9,750,961,110	-
Workers' Profit Participation Fund and Welfare Fund	959,165,296	994,392,153
<b>Tk.</b>	<b><u>15,564,534,564</u></b>	<b><u>3,512,907,803</u></b>
<b>15. Current Tax Liabilities: Tk. 1,179,910,862</b>		
Opening Balance	912,265,905	356,095,553
Provision made for the Period/Year	2,234,244,820	4,567,377,453
Payment made during the Period/Year	(1,966,599,863)	(4,011,207,101)
<b>Tk.</b>	<b><u>1,179,910,862</u></b>	<b><u>912,265,905</u></b>
<b>16. Accrued Expenses: Tk. 260,310,524</b>		
Accrued Expenses	260,210,524	284,549,448
Audit Fees	100,000	1,100,000
<b>Tk.</b>	<b><u>260,310,524</u></b>	<b><u>285,649,448</u></b>
<b>17. Unclaimed Dividend: Tk. 186,111,773</b>		
Opening Balance	191,983,629	158,997,790
Addition during the Period/Year	-	81,227,751
Paid to shareholders during the Period/Year	(5,871,856)	(10,542,278)
Transferred to CMS Fund during the Period/Year	-	(37,699,634)
<b>Tk.</b>	<b><u>186,111,773</u></b>	<b><u>191,983,629</u></b>
	<u>July'24 - Dec'24</u>	<u>July'23 - Dec'23</u>
<b>18. Net Revenue: Tk. 29,896,175,660</b>		
<b>Local:</b>		
Gross Revenue	33,993,741,858	36,293,651,905
Value Added Tax	(4,378,353,682)	(5,256,967,590)
<b>Revenue without VAT</b>	<b><u>29,615,388,176</u></b>	<b><u>31,036,684,315</u></b>
Discount	(1,112,071,225)	(1,173,029,422)
<b>Net Revenue - Local</b>	<b><u>28,503,316,951</u></b>	<b><u>29,863,654,893</u></b>
Export Revenue - Equivalent to US \$11,661,087 (Jul'23-Dec'23: US \$11,525,880)	1,392,858,710	1,170,224,404
<b>Tk.</b>	<b><u>29,896,175,660</u></b>	<b><u>31,033,879,297</u></b>
<b>19. Cost of Goods Sold: Tk. 17,308,352,978</b>		
Raw Materials Consumed (Note - 19.1)	7,369,307,698	6,782,599,373
Packing Materials Consumed (Note - 19.2)	3,874,825,721	3,430,377,619
<b>Cost of Materials Consumed</b>	<b><u>11,244,133,419</u></b>	<b><u>10,212,976,991</u></b>
Add: Manufacturing Overhead (Note - 19.3)	4,774,670,118	4,077,411,591
<b>Total Manufacturing Cost</b>	<b><u>16,018,803,537</u></b>	<b><u>14,290,388,582</u></b>
Add: Opening Work-in-Process	582,783,730	534,754,619
Less: Closing Work-in-Process	(669,632,733)	(528,709,822)
<b>Cost of Goods Manufactured</b>	<b><u>15,931,954,534</u></b>	<b><u>14,296,433,379</u></b>
Add: Opening Finished Goods	3,531,153,695	3,322,480,192
Add: Purchase of Finished Goods	1,937,318,643	1,736,673,630
Less: Cost of Physician Sample	(110,549,689)	(112,724,181)
<b>Cost of Goods Available for Sale</b>	<b><u>21,289,877,183</u></b>	<b><u>19,242,863,021</u></b>
Less: Closing Finished Goods	(3,981,524,205)	(3,510,109,012)
<b>Tk.</b>	<b><u>17,308,352,978</u></b>	<b><u>15,732,754,009</u></b>
<b>19.1 Raw Materials Consumed: Tk. 7,369,307,698</b>		
Opening Stock	3,722,861,831	3,389,777,254
Purchased during the Period	8,034,163,286	6,570,003,972
Closing Stock	(4,387,717,419)	(3,177,181,853)
<b>Tk.</b>	<b><u>7,369,307,698</u></b>	<b><u>6,782,599,373</u></b>
<b>19.2 Packing Materials Consumed: Tk. 3,874,825,721</b>		
Opening Stock	1,091,402,281	1,059,984,113
Purchased during the Period	4,111,745,608	3,354,954,866
Closing Stock	(1,328,322,168)	(984,561,360)
<b>Tk.</b>	<b><u>3,874,825,721</u></b>	<b><u>3,430,377,619</u></b>
<b>19.3 Manufacturing Overhead: Tk. 4,774,670,118</b>		
Salaries & Allowances	1,589,180,038	1,337,966,975
Contribution to Provident Fund	47,408,850	31,678,309
Entertainment, Staff Lunch & Refreshments	91,190,524	73,915,665
Training & Development	636,753	356,224
Staff Uniform	58,913,847	57,360,633
Travelling & Conveyance	31,392,277	24,980,327
US FDA User Fees	82,628,520	73,149,378
Laboratory Consumables	342,875,259	315,889,087
Research & Product Development	186,586,709	62,372,698
Printing & Stationery	45,414,117	41,005,558
Courier, Telephone, Cell phone & Internet	5,137,423	5,028,516
Rental Expenses	649,710	605,110
Utilities Expense	618,126,215	584,342,018
Sanitation Expenses	107,738,866	63,238,294
Petrol, Oil & Lubricants	138,193,590	87,819,117
Generator Rental Expenses	18,000,000	7,300,000
Repairs & Maintenance - Factory	586,586,092	500,084,445
Repairs & Maintenance - Vehicle	61,171,837	57,262,452
Insurance Premium	21,809,114	20,745,197
Security Services	41,990,553	31,975,427
Govt. Taxes & License Fees	15,043,055	16,355,759
Toll Charges	81,819,230	36,412,074
Software, Hardware Support & VSAT Services	33,577,747	27,007,430
Depreciation	567,291,590	620,303,227
Other Expenses	1,308,202	257,671
<b>Tk.</b>	<b><u>4,774,670,118</u></b>	<b><u>4,077,411,591</u></b>

	July'24 - Dec'24	July'23 - Dec'23																																																	
<b>20. Selling and Distribution Expenses: Tk. 5,954,028,247</b>																																																			
Salaries & Allowances	945,117,527	848,583,397																																																	
Contribution to Provident Fund	78,042,481	60,994,263																																																	
Entertainment, Staff Lunch & Refreshments	22,240,509	21,839,082																																																	
Training & Development	5,838,983	4,956,575																																																	
Staff Uniform	3,518,860	3,173,253																																																	
Travelling & Conveyance	89,216,063	86,468,101																																																	
Printing & Stationery	49,425,366	43,723,162																																																	
Courier, Telephone, Cell phone & Internet	49,894,682	40,969,944																																																	
Office & Godown Rent	18,981,083	16,581,826																																																	
Utilities Expense	25,531,125	22,245,556																																																	
Sanitation Expenses	10,897,599	10,313,091																																																	
Field Staff Salaries, Allowances, TA & DA	1,947,780,246	1,794,297,785																																																	
Target Incentive to Field Staff	233,992,009	247,254,859																																																	
Promotional Expenses	563,300,475	587,511,689																																																	
Marketing Expenses	607,188,114	335,496,810																																																	
Pharmacovigilance	34,073,829	78,803,319																																																	
Marketing Website Platform Software Maintenance	7,535,633	5,651,840																																																	
Event, Programs & Conference	146,957,044	105,564,370																																																	
Literature & Publications	88,184,557	68,021,022																																																	
Market Research & Survey Expenses	12,661,447	9,247,561																																																	
Advertisement	756,000	130,000																																																	
Delivery & Packing Expenses	152,594,665	131,999,496																																																	
Export Expenses	165,881,949	65,605,851																																																	
Repairs & Maintenance - Office	35,899,902	32,919,121																																																	
Repairs & Maintenance - Vehicle	302,250,877	283,765,181																																																	
Insurance Premium	3,162,593	2,939,048																																																	
Security Services	56,537,996	47,617,220																																																	
Govt. Taxes & License Fees	26,519,661	18,327,656																																																	
Bank Charges	8,181,733	8,708,194																																																	
Software, Hardware Support & VSAT Services	37,763,617	26,517,737																																																	
Depreciation	113,389,371	114,963,266																																																	
Other Expenses	110,712,251	112,921,492																																																	
<b>Tk.</b>	<b>5,954,028,247</b>	<b>5,238,111,767</b>																																																	
<b>21. Administrative Expenses: Tk. 881,733,530</b>																																																			
Salaries & Allowances	291,434,411	262,263,484																																																	
Contribution to Provident Fund	7,482,640	5,954,709																																																	
Directors' Remuneration	44,437,500	44,437,500																																																	
Entertainment, Staff Lunch & Refreshments	39,045,477	35,589,139																																																	
Training & Development	3,288,068	3,019,293																																																	
Staff Uniform	904,725	851,579																																																	
Travelling & Conveyance	90,163,957	80,098,529																																																	
Printing & Stationery	10,642,980	9,844,967																																																	
Courier, Telephone, Cell phone & Internet	6,628,549	5,004,918																																																	
Office Rent	13,085,082	10,172,688																																																	
Utilities Expense	16,995,909	14,075,250																																																	
Sanitation Expenses	5,588,248	4,769,009																																																	
Subscription & Donation	2,615,200	2,435,000																																																	
Legal & Professional Fees	3,840,167	1,851,850																																																	
Repairs & Maintenance - Office	103,545,407	94,162,270																																																	
Repairs & Maintenance - Vehicle	43,819,490	39,754,375																																																	
Insurance Premium	14,562,520	12,293,026																																																	
Security Services	33,670,507	26,894,678																																																	
Govt. Taxes & License Fees	15,272,035	38,125,489																																																	
Bank Charges	3,634,591	4,945,514																																																	
Software & Hardware Support Services	4,469,501	5,355,675																																																	
Depreciation	120,432,032	114,571,004																																																	
Other Expenses	6,174,534	3,810,638																																																	
<b>Tk.</b>	<b>881,733,530</b>	<b>820,280,584</b>																																																	
<b>22. Other Operating Income: Tk. 1,713,803,860</b>																																																			
Rental Income	8,187,708	8,076,706																																																	
Sale of Scrap	30,972,838	26,181,401																																																	
Gain on Fluctuation of Foreign Currency	184,149,451	94,290,139																																																	
Cash Incentive Received against Export	2,417,200	22,924,800																																																	
Commission Received	1,478,455,972	864,849,919																																																	
P.F Forfeiture Amount	934,049	261,253																																																	
Gain/(Loss) on Disposal of Property, Plant and Equipment	8,686,642	-																																																	
<b>Tk.</b>	<b>1,713,803,860</b>	<b>1,016,584,218</b>																																																	
<b>23. Income from Investments: Tk. 3,053,735,856</b>																																																			
Interest from Deposits	1,810,992,019	1,472,360,382																																																	
Interest from Short Notice Deposits	671,593,561	407,895,069																																																	
Gain on Redemption of Zero Coupon Bond	17,688,683	34,547,098																																																	
Interest from Subordinate Bonds	335,079,562	207,217,424																																																	
Dividend Income	125,189,112	14,816,295																																																	
Gain on Sale of Marketable Securities (Realized)	93,192,919	852,558																																																	
<b>Tk.</b>	<b>3,053,735,856</b>	<b>2,137,688,825</b>																																																	
<b>24. Income Tax Expenses: Tk. 2,173,597,001</b>																																																			
Current Tax Expense	2,234,244,820	2,526,922,772																																																	
Deferred Tax Expense / (Income)	(60,647,819)	83,766,623																																																	
<b>Tk.</b>	<b>2,173,597,001</b>	<b>2,610,689,395</b>																																																	
<b>24.1 Reconciliation of Effective Tax Rate:</b>	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="2">July'24 - Dec'24</th> <th colspan="2">July'23 - Dec'23</th> </tr> <tr> <th>%</th> <th>Taka</th> <th>%</th> <th>Taka</th> </tr> </thead> <tbody> <tr> <td>Profit before Tax</td> <td></td> <td style="text-align: right;">10,018,661,350</td> <td></td> <td style="text-align: right;">11,806,656,814</td> </tr> <tr> <td>Income Tax using Corporate Tax Rate</td> <td style="text-align: right;">22.50%</td> <td style="text-align: right;">2,254,198,804</td> <td style="text-align: right;">22.50%</td> <td style="text-align: right;">2,656,497,783</td> </tr> <tr> <td>Effects of:</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Income Exempted from Tax</td> <td style="text-align: right;">-0.45%</td> <td style="text-align: right;">(45,413,580)</td> <td style="text-align: right;">-0.07%</td> <td style="text-align: right;">(7,773,097)</td> </tr> <tr> <td>Income Taxed at Reduced Rate</td> <td style="text-align: right;">-0.35%</td> <td style="text-align: right;">(35,188,223)</td> <td style="text-align: right;">-0.32%</td> <td style="text-align: right;">(38,035,291)</td> </tr> <tr> <td>Effective Income Tax</td> <td style="text-align: right;">21.70%</td> <td style="text-align: right;">2,173,597,001</td> <td style="text-align: right;">22.11%</td> <td style="text-align: right;">2,610,689,395</td> </tr> <tr> <td>Effect of Deferred Tax</td> <td style="text-align: right;">0.61%</td> <td style="text-align: right;">60,647,819</td> <td style="text-align: right;">-0.71%</td> <td style="text-align: right;">(83,766,623)</td> </tr> <tr> <td>Effective Current Tax</td> <td style="text-align: right;"><b>22.30%</b></td> <td style="text-align: right;"><b>2,234,244,820</b></td> <td style="text-align: right;"><b>21.40%</b></td> <td style="text-align: right;"><b>2,526,922,772</b></td> </tr> </tbody> </table>		July'24 - Dec'24		July'23 - Dec'23		%	Taka	%	Taka	Profit before Tax		10,018,661,350		11,806,656,814	Income Tax using Corporate Tax Rate	22.50%	2,254,198,804	22.50%	2,656,497,783	Effects of:					Income Exempted from Tax	-0.45%	(45,413,580)	-0.07%	(7,773,097)	Income Taxed at Reduced Rate	-0.35%	(35,188,223)	-0.32%	(38,035,291)	Effective Income Tax	21.70%	2,173,597,001	22.11%	2,610,689,395	Effect of Deferred Tax	0.61%	60,647,819	-0.71%	(83,766,623)	Effective Current Tax	<b>22.30%</b>	<b>2,234,244,820</b>	<b>21.40%</b>	<b>2,526,922,772</b>	
	July'24 - Dec'24		July'23 - Dec'23																																																
	%	Taka	%	Taka																																															
Profit before Tax		10,018,661,350		11,806,656,814																																															
Income Tax using Corporate Tax Rate	22.50%	2,254,198,804	22.50%	2,656,497,783																																															
Effects of:																																																			
Income Exempted from Tax	-0.45%	(45,413,580)	-0.07%	(7,773,097)																																															
Income Taxed at Reduced Rate	-0.35%	(35,188,223)	-0.32%	(38,035,291)																																															
Effective Income Tax	21.70%	2,173,597,001	22.11%	2,610,689,395																																															
Effect of Deferred Tax	0.61%	60,647,819	-0.71%	(83,766,623)																																															
Effective Current Tax	<b>22.30%</b>	<b>2,234,244,820</b>	<b>21.40%</b>	<b>2,526,922,772</b>																																															
<b>25. Unrealised Gain/(Loss) on Marketable Securities: Tk. 139,305,006</b>																																																			
Closing Unrealised Gain/(Loss)	(179,487,280)	817,968,968																																																	
Less: Opening Unrealised Gain/(Loss)	(318,792,286)	816,119,218																																																	
<b>Tk.</b>	<b>139,305,006</b>	<b>1,849,750</b>																																																	

	July'24 - Dec'24	July'23 - Dec'23
<b>26. Net Asset Value (NAV) per Share: Tk. 117.33</b>		
Net Asset attributable to the Ordinary Shareholders	104,007,632,114	105,795,119,620
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk.</b>	<b>117.33</b>	<b>119.35</b>
<b>27. Earnings per Share (EPS): Tk. 8.85</b>		
Net Profit after Tax attributable to Shareholders	7,845,064,349	9,195,967,419
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk.</b>	<b>8.85</b>	<b>10.37</b>
<b>28. Net Operating Cash Flow (NOCF) per Share: Tk. 7.51</b>		
Net Cash Generated from Operating Activities (Note - 28.1)	6,657,480,845	12,300,105,047
Number of Shares outstanding	886,451,010	886,451,010
<b>Tk.</b>	<b>7.51</b>	<b>13.88</b>
Due to Eid holiday in June 2023, additional credit facility were provided to the local customers which were collected during July'23 - Dec'23. Additionally, the Company received Insurance claim against the fire incident of LVP. These two factors caused a spike in the NOCF per share in July'23- Dec'23. There is no such factors in this period. Therefore, the NOCF per share seen a decline in the current period.		
<b>28.1 Reconciliation of Net Profit with Cash Flows Generated from Operating Activities:</b>		
<b>Profit after Tax</b>	<b>7,845,064,349</b>	<b>9,195,967,419</b>
Adjustments for:		
Non-Cash Income/Expenses:		
Depreciation	801,112,993	849,837,496
Effect of Exchange Rate Fluctuations	(184,149,451)	(78,264,046)
Deferred Tax (Expense) / Income	(60,647,819)	83,766,623
	<u>556,315,723</u>	<u>855,340,073</u>
Non-Operating Income/Expenses:		
Income from Investments (Note - 23)	(3,053,735,856)	(2,137,688,825)
(Gain)/Loss on Disposal of Property, Plant and Equipment (Note - 22)	(8,686,642)	-
	<u>(3,062,422,498)</u>	<u>(2,137,688,825)</u>
Changes in Working Capital:		
(Increase)/Decrease in Current Assets:		
Inventories	(1,080,473,976)	(37,061,544)
Trade Receivables	(211,729,478)	575,278,010
Other Receivables	(409,987)	1,160,324,506
Advances, Deposits and Prepayments	43,674,652	96,458,749
Increase/(Decrease) in Current Liabilities:		
Trade Payables	(175,509,624)	1,804,362,117
Other Payables	2,300,665,651	(21,131,272)
Current Tax Liabilities	467,644,957	658,722,991
Accrued Expenses	(25,338,924)	149,532,823
	<u>1,318,523,271</u>	<u>4,386,486,380</u>
<b>Net Cash from Operating Activities</b>	<b>Tk. 6,657,480,845</b>	<b>12,300,105,047</b>
<b>29. Contingent Liabilities:</b>		
1. Liabilities for at Sight Letter of Credits as of 31 December 2024 was Tk. 7,283,395,575.		
2. Corporate Guarantee in favour of Square Pharmaceuticals Kenya EPZ Ltd. for USD 8.00 Million is still in place with due approval of Bangladesh Bank.		
<b>30. Related Party Transactions:</b>		
<b>30.1 Transaction with Key Management Personnel:</b>		
Amount of compensation paid to Key Management Personnel including Board of Directors during the Period:		
Short-Term Employee Benefits	Tk. 245,508,915	220,019,420
Post-Employment Benefits	Tk. 4,619,095	12,618,525
Other Long-Term Benefits	-	-
Termination Benefits	-	-
Share-Based Payment	-	-
<b>30.2 Transaction with Other Related parties:</b>		
<b>A. Associates:</b>		
<b>Square Textiles Ltd. (46.36% share):</b>		
Opening Balance	-	-
Addition during the Period	5,386,200,000	2,946,700,000
Realized during the Period	(5,386,200,000)	(1,467,548,000)
<b>Tk.</b>	<b>-</b>	<b>1,479,152,000</b>
<b>Square Fashions Ltd. (48.63% share):</b>		
Opening Balance	-	-
Addition during the Period	11,846,581,422	3,121,635,221
Realized during the Period	(11,846,581,422)	(3,162,284,043)
<b>Tk.</b>	<b>-</b>	<b>(40,648,822)</b>
<b>Square Hospitals Ltd. (49.94% share):</b>		
Opening Balance	-	-
Addition during the Period	22,752,620	19,093,077
Realized during the Period	(22,752,620)	(19,093,077)
<b>Tk.</b>	<b>-</b>	<b>-</b>
<b>B. Subsidiaries:</b>		
<b>Square Lifesciences Ltd. (99.95% share):</b>		
Opening Balance	(1,616,263,960)	2,429,691,285
Addition during the Period	8,594,445,852	4,612,813,802
Realized during the Period	(10,712,247,475)	(6,439,988,040)
<b>Tk.</b>	<b>(3,734,065,583)</b>	<b>602,517,047</b>
<b>C. Subsidiaries of Associates:</b>		
<b>Square Denims Ltd. (Subsidiary of Square Fashions Ltd.):</b>		
Opening Balance	-	-
Addition during the Period	778,781,543	819,568,800
Realized during the Period	(778,781,543)	(819,568,800)
<b>Tk.</b>	<b>-</b>	<b>-</b>
<b>Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.):</b>		
Opening Balance	-	-
Addition during the Period	279,637,035	987,616,079
Realized during the Period	(279,637,035)	(987,616,079)
<b>Tk.</b>	<b>-</b>	<b>-</b>
<b>D. Others:</b>		
<b>Square InformatiX Ltd. (Service Provider):</b>		
Opening Balance	-	-
Addition during the Period	95,681,244	72,613,109
Realized during the Period	(95,681,244)	(72,613,109)
<b>Tk.</b>	<b>-</b>	<b>-</b>

	July'24 - Dec'24	July'23 - Dec'23
<b>Square Toiletries Ltd. (Supplier):</b>		
Opening Balance	-	-
Addition during the Period	87,214,911	63,354,650
Realized during the Period	(87,214,911)	(63,354,650)
<b>Tk.</b>	<b>-</b>	<b>-</b>
<b>Square Food &amp; Beverages Ltd. (Supplier):</b>		
Opening Balance	-	-
Addition during the Period	81,591,004	51,285,349
Realized during the Period	(81,591,004)	(51,285,349)
<b>Tk.</b>	<b>-</b>	<b>-</b>
<b>Square Securities Management Ltd. (Portfolio Manager):</b>		
Opening Balance	10,037,386	121,108,758
Addition during the Period	460,198,609	3,313,589,996
Realized during the Period	(423,421,019)	(3,306,447,613)
<b>Tk.</b>	<b>46,814,976</b>	<b>128,251,141</b>
<b>Pharma Packages (Pvt.) Ltd. (Supplier):</b>		
Opening Balance	71,489,278	5,746,842
Addition during the Period	161,730,651	1,247,874,182
Realized during the Period	(223,485,460)	(800,000,000)
<b>Tk.</b>	<b>9,734,469</b>	<b>453,621,024</b>
<b>AEGIS Services Ltd. (Service Provider):</b>		
Opening Balance	-	-
Addition during the Period	231,276,924	161,994,074
Realized during the Period	(231,276,924)	(161,994,074)
<b>Tk.</b>	<b>-</b>	<b>-</b>